Open an account

Biomea Fusion

BMEA · NASDAQ

$0.7356−$0.0999 (−11.96%)TodayMarket closed ·
Prev close $0.8355

About BMEA

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 41 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.

Employees
41
Headquarters
San Carlos, California
Listed
Apr 16, 2021
Sector
Health Care
Industry
Biotechnology
Website
biomeafusion.com

BMEA key statistics

Market cap
53.32M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.13M
Volume
3.55M
Open price
$0.8398
High today
$0.9128
Low today
$0.7355
52 Week high
$2.24
52 Week low
$0.7995

Biomea Fusion (BMEA) at a glance

Biomea Fusion (BMEA) last traded at $0.7356, with a market cap of 53.32M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.7355 and $0.9128. The current price is 0.0% above the day's low and 19.4% below its high.

Volume so far is 3.55M shares, in line with the average of 3.13M shares a day.

Over the past year Biomea Fusion has ranged from $0.7995 to $2.24, and now sits -4% of the way up that range.

Biomea Fusion met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.12 per share against an estimate of -$0.2282.

The average analyst price target is $6.63, 801.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $6.63
Low
$4.04
Now
$0.7356
High
$9.45

BMEA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 51.4% on average.

  1. Q3 FY24: reported -$0.91 per share against an estimate of -$0.9688
  2. Q4 FY24: reported -$0.81 per share against an estimate of -$0.9395
  3. Q1 FY25: reported -$0.80 per share against an estimate of -$0.624
  4. Q2 FY25: reported -$0.51 per share against an estimate of -$0.5412
  5. Q3 FY25: reported -$0.27 per share against an estimate of -$0.2609
  6. Q4 FY25: reported $0.27 per share against an estimate of -$0.2565
  7. Q1 FY26: reported -$0.17 per share against an estimate of -$0.2423
  8. Q2 FY26: reported -$0.12 per share against an estimate of -$0.2282

BMEA news

  • Tanya Rawat

    What’s Going On With Biomea Fusion (BMEA) Stock After Hours?

  • Press releaseGlobe Newswire

    Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

  • Tanya Rawat

    Biomea Fusion Stock Climbs 7% After-Hours: What's Going On?

  • Press releaseGlobe Newswire

    Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

  • Vandana Singh

    Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data

  • Tanya Rawat

    Biomea Fusion Shares Fall 19% After Hours: Here’s Why

  • Press releaseGlobe Newswire

    Biomea Fusion to Participate in Upcoming Investor Conferences

  • Henry Khederian

    Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion

Similar companies

Companies in the same industry as Biomea Fusion

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.